Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.80 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4006513 | 0.94 | EPHX2 (0.78) | EPHX2TSHRKMT2AMEN1RAB9A | |
| SCHEMBL4006508 | 0.94 | EPHX2 (0.78) | EPHX2TSHRKMT2AMEN1RAB9A | |
| SCHEMBL612863 | 0.87 | KMT2A (0.77) | EPHX2TSHRKMT2AMEN1RAB9A | |
| SCHEMBL5243682 | 0.86 | KMT2A (0.78) | EPHX2TSHRKMT2AMEN1RAB9A | |
| SCHEMBL5243125 | 0.86 | KMT2A (0.78) | EPHX2TSHRKMT2AMEN1RAB9A | |
| SCHEMBL5244903 | 0.86 | KMT2A (0.78) | EPHX2TSHRKMT2AMEN1RAB9A | |
| SCHEMBL5245634 | 0.85 | KMT2A (0.98) | EPHX2TSHRKMT2AMEN1RAB9A | |
| SCHEMBL609708 | 0.85 | EPHX2 (0.77) | EPHX2TSHRKMT2AMEN1RAB9A | |
| SCHEMBL612761 | 0.85 | EPHX2 (0.77) | EPHX2TSHRKMT2AMEN1RAB9A | |
| SCHEMBL5245302 | 0.84 | TSHR (1.00) | EPHX2TSHRKMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101133026-B | 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus | HOFFMANN LA ROCHE | 2011-07-06 | — | — | CN | claimed |
| CN-101133026-A | 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | CN | claimed |
| EP-1866285-A1 | 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. Hoffmann-Roche AG (CH) | 2007-12-19 | — | — | EP | claimed |
| WO-2006094633-A1 | 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | claimed |
| CN-101133026-B | 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus | HOFFMANN LA ROCHE | 2011-07-06 | — | — | CN | disclosed |
| CN-101133026-A | 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | CN | disclosed |
| EP-1866285-A1 | 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. Hoffmann-Roche AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006094633-A1 | 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199816-A1 | Aryl sulfonyl piperidines | GILLESPIE PAUL | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199816-A1 | Aryl sulfonyl piperidines | GPR119, SLC5A2, GLS2 | EPHX2 3131/4885TSHR 761/4885KMT2A 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.